Author

S. Stacchiotti

h-index 82 View on Semantic Scholar

We have 4 of 478 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial.

What is this summary about?This summary describes the main findings of the MANEUVER clinical trial for pimicotinib, a once-daily treatment. The goal was to see if pimicotinib could significantly reduce tumor size after 24 weeks of treatment in clinical trial participants with tenosynovial giant cell tumor (TGCT) comp...

H. Gelderblom, Xiao-Hui Niu, S. Stacchiotti et al. · Future Oncology · 0 citations

Review Open access Oct 2026

Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial

Abstract Background Tenosynovial giant cell tumor (TGCT) is a locally aggressive neoplasm caused by colony-stimulating factor 1 (CSF1) gene dysregulation. Vimseltinib is an oral, switch-control tyrosine kinase inhibitor of the CSF1 receptor. In part 1 of the MOTION phase 3 trial, vimseltinib demonstrated statistically...

V. Bhadri, H. Gelderblom, S. Stacchiotti et al. · The Oncologist · 0 citations

Editorial Sep 2026

Growth in oncology clinical trials and decline of independent research: Insights from the 22nd AIFA National Report on clinical trials.

The 22nd National Report on Clinical Trials of Medicinal Products published by the Italian Medicines Agency (AIFA) in July 2026 highlights contrasting trends in Italian clinical research. In 2024, 669 prospective clinical trials were authorized, the highest number recorded in the last three years. Oncology and hemato-o...

C. Cagnazzo, S. Stacchiotti, G. Procopio · Tumori · 0 citations

Open access Aug 2026

Histone deacetylase activity limits the response to EZH2 inhibition-based therapy in epithelioid sarcoma and is targetable by epigenetic combination

Findings identify failure to accumulate H3K27 acetylation as a hallmark of resistance to EZH2 inhibition-based treatment, and show that pharmacological HDAC inhibition can restore this chromatin transition and re-sensitize resistant tumors, providing a rationale for combined epigenetic targeting strategies in INI1-defi...

N. Arrighetti, C. Soffientini, V. Zuco et al. · bioRxiv · 1 citation